Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer

被引：29

作者：

Bouberhan, Sara ^{[1
,2
]}

Pujade-Lauraine, Eric ^{[3
]}

Cannistra, Stephen A. ^{[1
,2
]}

机构：

[1] Beth Israel Deaconess Med Ctr, 330 Brookline Ave,KS 113, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Assoc Res Canc Including Gynecol, Grp Natl Investigators Study Ovarian Canc & Breas, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 27期

关键词：

RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; BRCA2 REVERSION MUTATIONS; CELL-FREE DNA; DOUBLE-BLIND; PRIMARY PERITONEAL; PHASE-3; TRIAL; OPEN-LABEL; CHEMOTHERAPY; BEVACIZUMAB;

D O I：

10.1200/JCO.19.00314

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2424 / +

页数：14

共 70 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer [J].

Aghajanian, Carol ;

Goff, Barbara ;

Nycum, Lawrence R. ;

Wang, Yan V. ;

Husain, Amreen ;

Blank, Stephanie V. .

GYNECOLOGIC ONCOLOGY, 2015, 139 (01) :10-16

[3] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[4] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[5]

[Anonymous], 2017, FDA APPR OL TABL MAI

[6] Reliability and validity of the functional assessment of cancer therapy-ovarian [J].

Basen-Engquist, K ;

Bodurka-Bevers, D ;

Fitzgerad, MA ;

Webster, K ;

Cella, D ;

Hu, SH ;

Gershenson, DM .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1809-1817

[7]

Beaumont J, 2007, J CLIN ONCOL S, V25

[8] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9] Safety and dose modification for patients receiving niraparib [J].

Berek, J. S. ;

Matulonis, U. A. ;

Peen, U. ;

Ghatage, P. ;

Mahner, S. ;

Redondo, A. ;

Lesoin, A. ;

Colombo, N. ;

Vergote, I. ;

Rosengarten, O. ;

Ledermann, J. ;

Pineda, M. ;

Ellard, S. ;

Sehouli, J. ;

Gonzalez-Martin, A. ;

Berton-Rigaud, D. ;

Madry, R. ;

Reinthaller, A. ;

Hazard, S. ;

Guo, W. ;

Mirza, M. R. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1784-1792

[10] Maintenance PARP inhibitor therapy: is maintaining quality of life enough? [J].

Bouberhan, Sara ;

Shea, Meghan ;

Cannistra, Stephen A. .

LANCET ONCOLOGY, 2018, 19 (10) :E504-E504

← 1 2 3 4 5 6 7 →